Сравнение
Lixisenatide vs. VK2735
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Метаболизм
Метаболизм
Номер CAS
320367-13-3
нет данных
Молекулярная масса
4858.5 g/mol
нет данных
Период полувыведения
3 h
нет данных
Последовательность
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2нет данных
Механизм действия
Lixisenatide
Lixisenatide is a 44-amino-acid peptide based on exendin-4 (see exenatide) with six additional lysine residues at the C-terminus. This modification increases stability against DPP-4 degradation. The short half-life (~3 hours) and plasma peak around mealtime explain the predominantly prandial effect — stronger postprandial glucose action, weaker fasting glucose effect than weekly GLP-1 RAs.
VK2735
VK2735 activates both the GLP-1 and the GIP receptor — a dual mechanism similar to that of tirzepatide, suppressing appetite and food intake.
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
5
1
из них на людях
5
1
Зафиксированные эффекты
3
2
Открытые противоречия
1
0
Задокументированные нежелательные явления
1
1
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Lixisenatide and VK2735?
- Lixisenatide is classified as "Метаболизм", while VK2735 is classified as "Метаболизм". Lixisenatide: Synthetic exendin-4 analog with a C-terminal lysine extension. Prandial GLP-1 RA focused on postprandial glucose. FDA-approved 2016 as Adlyxin; EMA-approved 2013 as Lyxumia. Sanofi discontinued US distribution in 2023. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Lixisenatide or VK2735?
- The highest available evidence level is "РКИ на людях" for Lixisenatide and "РКИ на людях" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Lixisenatide and VK2735 in Germany and the United States?
- Германия: Lixisenatide — Рецептурный, VK2735 — Не одобрено. США: Lixisenatide — Не одобрено, VK2735 — Не одобрено. These are factual summaries with source and review date on the individual pages.